睾酮恢复后PSA动力学与非转移性前列腺癌进展及转移结局的差异关联
该研究汇总2项随机试验中接受放疗联合雄激素剥夺治疗的局限性前列腺癌患者数据,采用贝叶斯联合模型分析睾酮恢复后PSA动态与进展及转移结局的关联。结果显示PSA斜率与进展风险呈方向性关联,但与转移结局的关联在不同建模框架下不一致且估计不精确。
要点
- 睾酮恢复后PSA斜率短PSADT与进展风险方向性升高相关,但可信区间宽。
- PSA斜率与无转移生存的关联方向相反,且不精确。
- 累计PSA暴露与任一终点无临床意义关联。
核心结论
- 睾酮恢复后PSA斜率与进展风险呈方向性关联,但与转移结局的关联不一致且不精确,尤其远处转移事件数有限。
研究设计与样本
- 汇总2项随机试验的个体患者数据,纳入461例接受放疗联合ADT的局限性前列腺癌患者,共1594次睾酮恢复后PSA测量,中位随访115个月。
主要发现
- 无进展生存:PSADT 12个月时HR为1.10(95%CrI 0.87-1.39),PSADT 6个月时HR为1.20(95%CrI 0.75-1.92),HR>1的后验概率78%。
- 无转移生存:PSADT 12个月时HR为0.80(95%CrI 0.61-1.02),PSADT 6个月时HR为0.63(95%CrI 0.37-1.04)。
- 累计PSA暴露与两个终点均无临床意义关联。
- 死亡删失模型中,PSADT 12个月时进展HR为1.27(95%CrI 0.98-1.64),远处转移HR为1.13(95%CrI 0.59-2.15),远处转移事件仅32例。
临床怎么用
- 睾酮恢复后PSA斜率可作为进展风险的参考指标,但尚不能据此对转移风险做出确定性推断。
局限性
- 远处转移事件数有限(n=32),导致转移结局估计不精确。
- 不同建模框架下转移结局关联不一致,无法得出确定性结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate-specific antigen (PSA) kinetics following testosterone recovery remain difficult to interpret in patients treated with definitive radiation therapy with androgen deprivation therapy (ADT). We evaluated the association between posttestosterone recovery PSA dynamics and progression and metastatic outcomes using Bayesian joint modeling. METHODS AND MATERIALS: Individual patient data were pooled from 2 randomized trials of localized prostate cancer treated with radiation therapy and ADT. Serial PSA measurements obtained up to 18 months after testosterone recovery to supracastrate levels (>50 ng/dL) and before progression were analyzed using Bayesian joint models linking longitudinal mixed-effects models of log-transformed PSA with survival submodels for progression-free survival and metastasis-free survival. Associations of PSA slope and cumulative PSA exposure (area under the curve) with event risk were estimated via shared random effects. Sensitivity analyses used Bayesian cause-specific joint models censoring deaths. RESULTS: The cohort included 461 patients contributing 1594 postrecovery PSA measurements with a median follow-up of 115 months. PSA slope was re-expressed as hazard ratios (HRs) at selected PSA doubling time (PSADT) values relative to stable PSA. For progression-free survival, shorter PSADT was associated with directionally higher hazards of progression or death (PSADT 12 months: posterior median HR, 1.10; 95% credible interval [CrI], 0.87-1.39; PSADT, 6 months: HR, 1.20; 95% CrI, 0.75-1.92) with 78% posterior probability of HR > 1. For metastasis-free survival, estimates were directionally opposite (PSADT, 12 months: HR, 0.80; 95% CrI, 0.61-1.02; PSADT, 6 months: HR, 0.63; 95% CrI, 0.37-1.04). Cumulative PSA exposure showed no clinically meaningful association with either endpoint. In death-censored Bayesian joint models, the PSADT 12-month HR was 1.27 (95% CrI, 0.98-1.64) for progression and 1.13 (95% CrI, 0.59-2.15) for distant metastasis, with imprecision for distant metastasis reflecting the limited number of metastatic events (n = 32). CONCLUSIONS: PSA slope after testosterone recovery was directionally associated with progression risk. Associations with metastatic outcomes were inconsistent across modeling frameworks and imprecisely estimated, particularly for distant metastasis because of the limited number of events. No definitive inference regarding metastatic risk should be drawn from these analyses.
引用
- Lichtman-Mikol S, Attia SK, Sun Y, et al. Differential Association of Posttestosterone Recovery PSA Kinetics With Progression and Metastatic Outcomes in Nonmetastatic Prostate Cancers. Int J Radiat Oncol Biol Phys. 2026. PMID: 42805409. doi:10.1016/j.ijrobp.2026.08.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。